RNAi in Man: Initial Results from ALN-VSP Phase I Clinical Trial
In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man...
View ArticleAlnylam RNAi Roundtable: ALN-VSP Proof of Mechanism Data
In May 2011, we held a roundtable discussion focused on our ALN-VSP program; specifically, the important proof of mechanism data that we had reported on earlier in the year. ALN-VSP RNAi Roundtable...
View ArticleALN-VSP Data at 2011 ASCO Meeting
At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with...
View ArticleClik here to view.
ALN-VSP Podcast Discussing Phase I Clinical Trial
In August 2011, we recorded a podcast around our ALN-VSP program for the treatment of liver cancers. The discussion was led by our own Jared Gollob, M.D., Senior Director of Clinical Research, and Dr....
View ArticleALN-VSP Historical Press Releases
For your convenience we have collected a list of historical releases that cover the historical progress of our clinical program for liver cancers* 2012 06/04/2012 Alnylam Presents Data from its Phase I...
View ArticleData from our ALN-VSP Phase I Extension Study Presented at ASCO
At the annual ASCO meeting in June 2012, we presented data from our ALN-VSP Phase I extension study. Overall, the results demonstrated disease control lasting more than six months in the majority of...
View Article
